CompletedPHASE2, PHASE3NCT02467608

Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis

Studying Primary pulmonary tuberculosis

Last synced from ClinicalTrials.gov May 18, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Orient Pharma Co., Ltd.
Principal Investigator: Yu-Pu Hu, PhD
National Defense Medical Center, Taiwan
Intervention: Isoniazid with HUEXC030 and RZE(drug)
Enrollment: 557 enrolled
Eligibility: 20 years · All sexes
Timeline: 2012 – 2019

Study locations (18)

Changhua Christian Hospital, Changhua, Taiwan
Changhua Hosiptal Ministry of Health And Welfare, Changhua, Taiwan
Chang Gung Memorial Hospital, ChiaYi, Chiayi City, Taiwan
Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung City, Taiwan
E-DA Hospital, I-Shou University, Kaohsiung City, Taiwan
Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan
Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan
Chang Gung Memorial Hospital ,Linkou, Linkou District, Taiwan
Taichung Veterans General Hospital, Taichung, Taiwan
Taipei Veterans General Hospital, Taipei, Taiwan
Tri-Service General Hospital, Taipei, Taiwan
Buddhist Tzu Chi General Hospital, Taipei, Taiwan
Cheng Hsin General Hospital, Taipei, Taiwan
National Taiwan University Hospital, Taipei, Taiwan
Taipei City Hospital, Taipei, Taiwan
+3 more locations on ClinicalTrials.gov

Collaborators

National Defense Medical Center, Taiwan · National Research Program for Biopharmaceuticals, Taiwan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02467608 on ClinicalTrials.gov

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Primary pulmonary tuberculosis →

← Back to all trials